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In order to determine the prevalence of vancomycin-resistant enterococci (VRE) in The Netherlands, 624 
hospitalized patients from intensive care units or hemato-oncology wards in nine hospitals and 2 0 0  patients 
living in the community were screened for VRE colonization. Enterococci were found in 49% of the hospitalized 
patients and in 80% of the patients living in the community. Of these strains, 43 and 32%, respectively, were 
Enterococcus faecium. VRE were isolated from 12 of 624 (2 %) and 4 of 200 (2%) hospitalized patients and 
patients living in the community, respectively. PCR analysis of these 16 strains and 11 additional clinical VRE 
isolates from one of the participating hospitals revealed 24 vanA gene-containing, 1 vanB gene-containing, and 
2 vanCl gene-containing strains. All strains were cross-resistant to avoparcin but were sensitive to the novel 
glycopeptide antibiotic LY333328. Genotyping of the strains by arbitrarily primed PCR and pulsed-field gel 
electrophoresis revealed a high degree of genetic heterogeneity. This underscores a lack of hospital-driven 
endemicity of VRE clones. It is suggested that the VRE in hospitalized patients have originated from unknown 
sources in the community.
Enterococcus spp. have recently emerged as important nos­
ocomial pathogens (35). According to the data from the Na­
tional Nosocomial Infections Surveillance System, enterococci 
are the fourth leading cause of nosocomial infections in the 
United States (12). Enterococcal infections that have fre­
quently been reported include urinary tract infections, bacte­
remia, endocarditis, intra-abdominal infections, and surgical 
wound infections (27). Enterococcus faecalis is commonly iso­
lated from the human gastrointestinal tract, whereas Entero­
coccus faecium is less frequently isolated from that site (31). 
This latter species, however, is noted for its antimicrobial re­
sistance. Vancomycin-resistant E. faecium (VREF) strains 
have emerged in a setting of increasing high-level resistance of 
enterococci to penicillins and aminoglycosides (28). During the 
last few years, nosocomial outbreaks due to VREF have been 
described (17, 25). The emergence of VREF has raised serious 
concerns (28), and in response, the Hospital Infections Control 
Practices Advisory Committee (HICPAC), in collaboration 
with the Centers for Disease Control and Prevention, has de­
veloped recommendations for preventing the spread of vanco­
mycin-resistant enterococci (VRE) (18). Given the concern 
that vancomycin resistance genes may transfer from entero­
cocci to Staphylococcus aureus, a phenomenon that has been 
observed in vitro (31), control measures have already been 
proposed, should vancomycin-resistant S. aureus strains even­
tually arise (10).
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The microbiology laboratory has an important role in the 
detection, reporting, and control of VRE. The HICPAC doc­
ument emphasizes the need for routine susceptibility testing of 
all enterococci isolated from clinical specimens. Furthermore, 
in hospitals where VRE have not yet been detected, periodic 
culture surveys of stools or rectal swabs of patients at high risk 
for VRE infection or colonization are indicated (18). In The 
Netherlands, no systematic study has been done to evaluate the 
prevalence of VRE infection or colonization in hospitalized 
patients or patients living in the community. Therefore, the 
present study was started to determine the prevalence of fecal 
carriage of VRE in hospitalized patients with an increased risk 
for infection or colonization with VRE and in patients living in 
the community. We determined the susceptibility of VRE to 
vancomycin, teicoplanin, avoparcin (a glycopeptide available 
throughout Europe as an additive in animal feed [15]), and 
LY333328 (a new glycopeptide antibiotic [37]). In order to 
determine the genetic basis of the glycopeptide resistance phe­
notype, PCR assays aimed at the various resistance genes were 
performed. Moreover, the VRE were typed by pulsed-field gel 
electrophoresis (PFGE), arbitrarily primed PCR (AP-PCR), 
and ribotyping to determine the degree of genetic relatedness 
of this group of resistant microorganisms.
MATERIALS AND METHODS
Prevalence study. Five Dutch university hospitals in Rotterdam, Utrecht, 
Nijmegen, and Amsterdam and four regional teaching hospitals in Breda and 
Tilburg participated in the study. Six hundred twenty-four patients who were 
hospitalized in the following wards were screened for gastrointestinal carriage of 
VRE: medical and surgical intensive care unit (ICU), thoracic surgical ICU, 
neurological and neurosurgical ICU, pediatric ICU (either surgical, neonatal, or 
general pediatric), and hemato-oncology wards. The prevalence study was car­
ried out in November 1995 and February 1996. In addition, 200 outpatients 
attending general practitioners for diarrhea were screened. For this latter group
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of patients no information was available on prior antibiotic exposure. Early and 
empiric treatment of bacterial diarrhea in patients living in the community is 
uncommon practice in The Netherlands.
Bacterial isolates. Sixteen strains of VRE isolated during the prevalence study 
were analyzed. Four of these 16 strains were isolated at Rotterdam University 
Hospital (hospital A). In addition, 11 clinical strains of VRE that were isolated 
in 1995 in hospital A before the start of the survey were studied. The 11 strains 
were isolated from patients with rectal colonization but without infection (n = 5), 
whereas the other strains were clear causes of nosocomial infection (urinaiy tract 
infections [« ^  2], cholecystitis [?? «  2], and soft tissue infection and peritonitis 
[n = 2]).
Culture and identification. Stool specimens or rectal swabs from all patients 
were cultured in a selective, escul in-con tain mg enrichment broth (1, 26) supple­
mented with 5(1 mg of cephalexin per liter and 75 mg of aztreonam (Bristol- 
Myers Squibb, Princeton, N.J.) per lifer. All csculin-positive broth cultures were 
subcultured on a new selective agar designed for isolation of E. faecium (14), with 
and without 6 mg of vancomycin per liter, and on Columbia blood agar. In a pilot 
study this procedure proved to be sensitive, very convenient, and easy since all 
broth cultures containing enterococci did turn black; all other broth cultures 
could be disregarded without further processing. All enterococcus-like, arabi- 
nosc-fcvmcnting, and arabinose-nonferrnenting colonies were subcultured. A 
presumptive identification of Enterococcus was made on the basis of colonial 
morphology. Gram staining result, eatalase and PYRase (Difco Laboratories, 
Detroit, Mich.) activities, and the presence of the Lanceficld group D antigen 
(13). Definitive identification was done with the API 32 rapid system (Bio- 
Merieux, Marcy I’Etoile, France). Enterococcus gallinarum was identified by 
digestion of DNA with Sma\ and PFGE, Strains for which all DNA fragments 
were <200 kb on PFGE were identified as E, gallmamm (7).
Susceptibility testing. Resistance to vancomycin was detected by the E-test 
(AB Btadisk, Solna, Sweden) (34). An inoculum with a turbidity equivalent to 
that of a 0.5 McFarland standard and Mucller-Hinton agar (Difco) were used. 
Plates were read after incubation at 37°C for 24 h, and the MICs obtained by the 
E-test were rounded to the nearest higher doubling dilution. All vancomycin- 
resistant enterococci (MICs, >4 mg/liter) were subjected to further susceptibility 
tests by standard agar dilution and broth dilution methods according to the 
guidelines of the National Committee tor Clinical Laboratory Standards (NC- 
CLS) (29). E. faeculis ATCC 29212 and .S’, aureus ATCC 29213 were used as 
reference strains. The following glycopeptide agents were tested: vancomycin 
(Eli Lilly & Co., Indianapolis, Ind.), leicoplanin (MMDRI-Lepetit Research 
Center, Gerenzano, Italy), avoparcin (Roche, Basel, Switzerland), and LY333328 
(Eli Lilly & Co.).
DNA isolation. DNA was isolated as described by Boom ct al, (4). The strains 
were grown overnight at 37°C on brucella blood agar plates. Colonies were 
suspended in TEG buffer (25 niM Tris-HCl IpH 8.0], 10 mM EDTA, 50 mM 
glucose). A lysozyine solution (10 mg/liter) was added, and this mixture was 
incubated for 1 h at 37°C. Guanidine hydrolhiocyanate was added for cell lysis, 
and Celite (Janssen Pharmaceuticals, Beerse, Belgium) was used for DNA bind­
ing. DNA was eluted with 10 mM Tris-HCl (pH 8.0), The DNA concentration 
was estimated by electrophoresis on a 1% agarose gel (Hispanagar; Sphacro G, 
Leiden, The Netherlands) containing ethidium bromide in the presence of 
known quantities of bacteriophage lambda DNA.
PCR assay for vauA> vault, and vanC genes. The PCR assays were performed 
as described earlier by Dulka-Malen el al. (9). Approximately 10 to 100 ng (10 
jxl) of DNA was added to a PCR mixture (90 fxl) containing 10 mM Tris-HCl (pH 
9.0), 50 mM KC1, 2.5 mM MgC'L, 0.01% gelatin, 0.1% Triton X-100, 0.2 mM 
(each) the four deoxyribonueleotide triphosphates, and 1.2 U of Taq DNA 
polymerase (Sphaero Q). Four different primer couples (\muA, vanB, vanCl, and 
imC2 [9]) were used in the assay (50 pmol of each primer per reaction mixture). 
Amplification of DNA was performed in a Biomed model toO thermocycler 
(Biomed, Theres, Germany) by using predenaturation al 94°C for 2 min, fol­
lowed by 30 cycles of I min at 94°C, 1 min at 54°C, and 1 min al 72°C. Amplicons 
were analyzed by electrophoresis on a 1% agarose gel (Gibco BRL, Brussels, 
Belgium) containing ethidium bromide in the presence of a 100-bp ladder.
Ribotyping. Restriction digestion of 20-|jd (5-jxg) samples of DNA was done by 
overnight incubation at 37°C with EcoRl (Boehringer GmbH, Mannheim, Ger­
many). DNA fragments were separated by electrophoresis on a 1% agarose gel 
for Ki h (30 V, 200 mA). Southern transfers of the gel with ZxoRI-digestcd DNA 
were made by capillary blotting onto a nylon membrane (Hyhond N+; Amer- 
sham, Buckinghamshire, Uniled Kingdom). The blots were hybridized with a 16S 
rRNA riboprobe. The probe was synthesized by PCR-mcdiated amplification of 
the ribosomal genes of Escherichia coli. The amplicon was purified by Qiaquick 
procedures (Westburg, Leusden, The Netherlands) and labelled by using ECL 
kits (Amersham), Further processing (hybridization, washing, and development) 
was done according to the guidelines provided with the ECL kil.
AP-PCR. AP-PCR was performed as described lufore (40). Approximately 5 
to 50 ng (10 (jil) of DNA was added to a PCR mixture (40 p.1) containing 10 mM 
Tris-HCl (pH 9.0), 50 mM KC1, 2.5 mM MgCl2, 0.01% gelatin, 0.1% Triton 
X-100, 0.2 mM (each) the deoxyribonucleotide triphosphates, and 1.2 U of Taq 
DNA polymerase. Four different primers were used in separate assays (50 pmol 
of primer per reaction mixture; ERIC-IR, 5'-ATG TAA GCT CCT GGG GAT 
TCA C-3'; ERIC-2, 5'-AAG TAA GTG ACT GGCr GTG AGC’ G-3'; AP-l, 
5'*GGT TOG GTG AGA ATT GCA CG-3'; AP-7, 5'-GTG GAT GCG A-3').
Amplification of DNA was performed in a Biomed model 60 thermocycler by 
using prcdcnaturation at 94°C for 4 min, followed by 40 cycles of 1 min at 94°C,
1 min at 25°C, and 2 min at 74°C. Banding patterns were visualized after 
electrophoresis on a 1% agarose gel containing ethidium bromide in the pres­
ence of; a 100-hp ladder. Banding patterns were interpreted by visual inspection. 
Different types were identified on the basis of even a single differentiating DNA 
fragment. Differences in ethidium bromide staining intensity were ignored.
PFGE. Ten colonics of an overnight culture grown on blood agar were sus­
pended in 100 p.1 of EETbuffer (100 mM sodium EDTA, 10 mM EGTA, 10 mM 
Tris-HCl [pH 8.0]). This suspension was mixed with J 00 fxl of 1 % agarose (Incert 
agarose; FMC Bioproducts Corp., Rockland, Maine), and the mixture was trans­
ferred into sample plug molds (final agarose concentration, 0.5%;). The plu^s 
were incubated for 4 h at 370C in 1 ml of EET buffer containing 10 mg of 
lysozyme (Sigma Chemical Co., St. Louis, Mo.). This lysis solution was replaced 
by a 1-ml EET buffer solution containing 1 mg of proteinase K and '1% sodium 
dodccyl suit ate for a further overnight incubation at 37°C. The plugs were 
washed six times (30 min each time at room temperature) in TE solution (10 mM 
Tris-HCl [pH 8.0], 1 mM EDTA). To digest the DNA, a 5-mm slice of the sample 
plug was placed in a TE solution (10 mM Tris-HCl [pH 8.0|, 0.1 mM EDTA) with 
40 U of Smal (Boehringer GmbH), and the mixture was incubated overnight at 
25°C. The plugs were loaded onto a 1% agarose ¿.¿1 (SeaKem GTG agarose; 
FMC) in 0.5 X TBE (Tris, borate, EDTA) (32). Eketrophoresis was performed 
with a CHEF D R  II apparatus (Bio-Rad, Richmon J, Calif.) programmed in the 
auto-algorithm mode (block 1, run time of 8 h ai d switch time of 0.5 to 15 s; 
block 2, run time of 10 h and switch time of 15 to 3C s). The gels were stained with 
ethidium bromide for 15 min and were destained i r distilled water for 1 h before 
photography. All gels were inspected visually fy two different investigators. 
Profiles were designated by a different capital litter any time that a distinct 
pattern (difference of four or more bands) was obtained. Isolates with identical 
profiles were assigned the same letter. Isolates that differed by one to three 
bands, consistent with a single genetic event, were assigned to a subtype (38).
Statistical analysis. Fisher’s two-tailed test was used to assess differences 
between frequencies of isolation of enterococci in the two different patient 
populations.
RESULTS
Three hundred six (49%) of the 624 hospitalized patients 
and 161 (80%) of 200 diarrheic patients living in the commu­
nity carried enterococci in their gastrointestinal tracts (P <
0.01). Of the 306 enterococci isolated from hospitalized pa­
tients, 132 (43%) were identified as E. faecium. Of 161 entero­
cocci from patients outside the hospital, 52 (32%) were iden­
tified as E. faecium (P <  0.05). Thus, E. faecium was isolated 
from 132 of 624 (21%) of the hospitalized patients and 52 of 
200 (26%) of the patients living in the community (P >  0.05). 
VRE were isolated from 12 (2%) of the 624 hospitalized pa­
tients and 4 (2%) of the 200 patients living in the community. 
Fifteen VRE were identified as E. faecium; one was identified 
as E. faecalis. Fifteen (8%) of 184 E. faecium strains isolated in 
the prevalence study were vancomycin resistant. In addition, 11 
strains of V RE  were isolated in hospital A  at times separate 
from the period of the prevalence study. Nine were identified 
as E. faecium, and two were identified as E. gallinanim. Thus, 
27 strains of VRE were available for further studies.
The susceptibilities of the 27 strains of VRE to vancomycin, 
teicoplanin, avoparcin, and LY333328 and the resistance ge­
notype are presented in Table 1. Complete cross-resistance 
between vancomycin and avoparcin was found. LY333328, 
however, was 250- to >  1,000-fold more active than vancomycin 
against vanA VRE. Major discrepancies were observed be­
tween the MICs of LY333328 that were determined by the agar 
dilution method and those determined by the broth dilution 
method: on agar, the M IC of LY333328 at which 90% of 
isolates are inhibited (M ICgn) for vanA VRE was 4 mg/liter 
(range, 0.25 to 4 mg/liter), whereas in broth the M IC90 was 0.5 
mg/liter (range, 0.125 to 1 mg/liter). We did not observe such 
differences with the other glycopeptide agents tested. Twenty- 
four of the 27 strains of VRE, including all VRE from the 
prevalence study, had the vanA genotype; 1 had the vanB 
genotype, and 2 had the vanCl genotype. For all vanA E. 
faecium isolates vancomycin MICs were >256 mg/liter and 
teicoplanin MICs were >64 mg/liter. For the vanB and vanCl
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VRE. The results of North American studies performed in the 
Houston, Texas, metropolitan area, however, contrast with the 
European data, since VRE appeared to be absent from healthy 
people in Houston (5). The level of colonization with VRE in 
people in the community in Europe parallels the level of col­
onization of animals with these resistant organisms (6). Several 
studies have now reported the absence of VRE from animals 
and people in the community in the United States, in contrast 
to the high frequencies in hospitals (5, 23, 39). Some investi­
gators, however, have cautioned against comparing the results 
of the studies mentioned above, since differences in method­
ology could, at least in part, explain the observed differences in 
isolation rates (5).
Since ICU patients and patients in oncology wards were 
found to be at increased risk for infection or colonization with 
VRE (18), we decided to select these patients for our inpatient 
survey. The rate of isolation of VRE from these hospitalized 
patients was 2% and, therefore, was similar to the rate of 
isolation from outpatients. This is roughly in agreement with 
the results of a recent Belgian study, in which it was shown that 
3.5% of hospitalized patients were carriers of VRE (16). In 
Finland, Suppola et al. (36) investigated hospitalized patients 
with hematological malignancies and reported a prevalence of
VRE of 2%.
We analyzed the genetic relatedness of the 27 VRE strains 
by PFGE and AP-PCR. In previous studies PFGE has been 
shown to be the most discriminating technique for typing iso­
lates of VRE, and this technique is now considered the “gold 
standard” (24, 25). Recently, however, AP-PCR has proven to 
be a powerful typing tool as well. Results of PFGE and AP- 
PCR are often in concordance (2). In our study, however, 
PFGE was more discriminatory than AP-PCR. Combining the 
data generated by the two methods, we demonstrated the ge­
netic unrelatedness of 13 of 16 strains of VRE isolated during 
the survey and of all 15 strains that were isolated in hospital A. 
No evidence of major inter- or intrahospital spread of VRE in 
The Netherlands exists. This observation is remarkable since 
no special infection control measures for preventing the trans­
mission of VRE were in place in the participating hospitals at 
the time of the survey. Together with the observed isolation 
rate of 2% for the patients living in the community, it is sug­
gested that VRE in hospitalized patients may have originated 
from unknown sources in the community. The gastrointestinal 
tract is probably the major reservoir in humans, from which 
subsequent infection can eventually develop. This is in agree­
ment with a recent report from New York City (32). Food has 
been proposed as a source (8, 28). Others have put forward 
pets and other domestic animals (6, 41). Furthermore, the use 
of antibiotics as feed additives for growth enhancement in 
animals may be associated with the emergence of VRE (22). 
An example of such a growth-promoting agent is avoparcin, a 
drug that has been used in The Netherlands for a long time. 
The production of pigs, poultry, and calves is an area of im­
portant economic activity in The Netherlands. To date, The 
Netherlands country is one of the leading exporters of con­
sumer poultry products in the world, after the United States 
and France (11). Although official figures are not available, it 
is clear that avoparcin has been used in The Netherlands on a 
very large scale. Preliminary results of a nationwide study of 
the prevalence of VRE in poultry suggest that approximately 
80% of the consumer poultry at the retail level is colonized 
with VRE, possibly as a result of the unrestricted use of 
avoparcin-in the poultry industiy (43). Thus, the use of oral 
glycopeptide antibiotics in the animal production industry 
should be strongly discouraged. Recently, the European Com­
munity committed itself to a cautious approach and banned all
use of avoparcin as feed additive in animals by 1 April 1997 
(12a).
The emergence of VRE has resulted in an increase in the 
incidence of infections that are caused by these organisms and 
that cannot be treated with currently available antimicrobial 
agents (19). LY333328 is a new semisynthetic glycopeptide that 
has been reported to have increased activity against vancomy­
cin-resistant gram-positive microorganisms (30). In our study, 
LY333328 was found to possess greatly enhanced activity 
against VRE. In general, the MICs of LY333328 were 25- to 
1,000-fold lower than those of vancomycin. These data are in 
agreement with those presented in an earlier report (37). Sur­
prisingly, the MICs of LY333328 obtained by an agar dilution 
method were four- to eightfold higher than those obtained by 
a broth dilution method, but we do not have an explanation for 
these discrepancies. This phenomenon has recently been re­
ported by others (20). The results, however, indicate that 
LY333328 is a promising new drug that deserves further eval­
uation. In conclusion, we have shown in a multicenter study 
that, first, VRE can be isolated from hospitalized patients and 
patients living in the community in The Netherlands at a fre­
quency of 2%. Second, these strains appear to be unrelated, 
and therefore, no evidence of major inter- or intrahospital 
spread of VRE strains in The Netherlands exists. Third, our 
data suggest that VRE are acquired outside the hospital envi­
ronment. Further studies are warranted to elucidate the origin 
and the epidemiology of vancomycin resistance. In countries 
with large populations of animal livestock, including The Neth­
erlands, where large quantities of feed additives are used, it 
seems wise to strongly discourage the use of oral glycopeptides 
not only in humans but in the animal production industry as 
well.
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